polycystic ovarian syndrome. Stein-Leventhal syndrome
Conditions
Interventions
Intervention 1: Intervention1: Letrozole( Letrozole Soha, Soha Pharmaceutical Company, Karaj, Iran), 2 tab 2.5 mg orally, since the 8th day up to human chorionic gonadotropin injections. Intervention
Treatment - Drugs
Placebo
Intervention1: Letrozole( Letrozole Soha, Soha Pharmaceutical Company, Karaj, Iran), 2 tab 2.5 mg orally, since the 8th day up to human chorionic gonadotropin injections
Intervention 2: Placebo, 2 tab 2.5 mg orally, since the 8th day up to human chorionic gonadotropin injections
Sponsors
Vice chancellor for research affairs, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Woman with clomiphene resistant PCOS; Infertility; Normal BMI; 18-35 years old. Exclusion criteria: Diabetes mellitus; Thyroid disease; Endocrinopathies; Breast cancer; Kidney or liver diseases; Autoimmune disorders; Smokers.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Premature LH surge. Timepoint: third day of experiment and the day of HCG. Method of measurement: measuring LH serum. | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of pregnancy. Timepoint: 6-7 weeks of pregnancy. Method of measurement: measuring B-HCG levels in serum.;Abortion rate. Timepoint: during pregnancy. Method of measurement: measuring B-HCG levels in serum and sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahere Bahrami Shabahrami
Department of Obstetrics and Gynecology and Student Research Committee
Outcome results
None listed